Figure S1. Representative immunohistochemical staining of PLS3 in non-small cell lung cancer samples. Representative immunohistochemical staining of PLS3 in (A) negative and (B) positive cases. Original magnification, x200; scale bar, 100 µm. PLS3, plastin 3.
Figure S2. Overall survival in patients with NSCLC treated with nivolumab according to each tested cut-off point of plasma PLS3 concentration. (A) Overall survival curves of patients with NSCLC divided into PLS3 ≤5.18 and >5.18 ng/ml groups. (B) Overall survival curves of patients with NSCLC divided into PLS3 ≤5.43 and >5.43 ng/ml groups. PLS3, plastin 3; NSCLC, non-small cell lung cancer.